Results were achieved at 48 hours in 10.7% of patients with NEMLUVIO +TCS/TCI vs 2.9% with placebo +TCS/TCI. Data are from pooled post-hoc analysis of daily itch improvement reported in Phase 3 clinical studies. Itch improvement was defined as ≥4‑point improvement from baseline (PP‑NRS scale). Do not make conclusions based on these results. Individual results may vary.
Ask your eczema specialist about Results were achieved at 48 hours in 10.7% of patients with NEMLUVIO +TCS/TCI vs 2.9% with placebo +TCS/TCI. Data are from pooled post-hoc analysis of daily itch improvement reported in Phase 3 clinical studies. Itch improvement was defined as ≥4‑point improvement from baseline (PP‑NRS scale). Do not make conclusions based on these results. Individual results may vary.
Not an actual patient.

Full Prescribing Information

Scroll

IMPORTANT SAFETY INFORMATION

INDICATION: NEMLUVIO® (nemolizumab-ilto) is a prescription medicine used to treat adults and children 12 years of age and older with moderate-to-severe eczema (atopic dermatitis or AD) in combination with prescription therapies used on the skin (topical) when the eczema is not well controlled by topical therapies alone.

Contraindication: Known hypersensitivity to NEMLUVIO or any ingredients in NEMLUVIO.

Warnings/Precautions: Hypersensitivity reactions have
been reported with NEMLUVIO use. You should not receive a live vaccine right before or during treatment with NEMLUVIO.

Adverse Events: Most common side effects of NEMLUVIO include: headache, joint pain, hives (itchy red rash or wheals) and muscle aches.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/‌medwatch or call 1-800-FDA-1088.

Please see full Prescribing Information including Patient Information.

©2026 Galderma Laboratories, L.P. All Rights Reserved.

NEMLUVIO is a registered trademark of Galderma.

US-NAD-2500044 01/26